Regaining compliance with Nasdaq's Minimum Bid Price Requirement is a significant positive development for Nektar Therapeutics. It removes the immediate risk of delisting, which can restore investor confidence and potentially lead to a more favorable market perception of NKTR's stock. This compliance indicates the company's ability to maintain a minimum stock price level, which is often seen as a sign of stability and financial health.